In response to a lawsuit filed by Myriad Geneics against rival Ambry Genetics accusing Ambry of patent infringement, Ambry has filed its own countersuit against its competitor for alleged antitrust violations. Reports say Ambry filed its own lawsuit in California on Tuesday, alleging Myriad’s initial claim violated antitrust law and “are invalid under two Supreme Court decisions and Federal Circuit authority.” The Supreme Court ruled last month that Myriad cannot hold patents on certain gene sequences. Myriad soon after filed a lawsuit claiming a testing process used by Ambry for detecting mutations in such gene sequences violated Myriad’s patent; Myriad claims that despite the Supreme Court ruling, it still holds valid claims in 24 patents.
Full Content: Genome Web
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Uruguayan Antitrust Scrutiny Puts Major Meatpacking Deal Between Marfrig and Minerva on Hold
May 19, 2024 by
CPI
Alaska Airlines Seeks Dismissal of Consumer Lawsuit Over $1.9 Billion Hawaiian Airlines Buy
May 19, 2024 by
CPI
Idaho Attorney General Orders Split of Kootenai Health and Syringa Hospital
May 19, 2024 by
CPI
Court Rejects T-Mobile’s Appeal Bid in Antitrust Case Over Sprint Merger
May 19, 2024 by
CPI
Google Requests Judge, Not Jury, to Decide on Antitrust Case
May 19, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI